ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product

Save

October 23, 2013 6:30 am EST

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that ZOSTAVAX® (Zoster Vaccine Live), the company’s
vaccine to help prevent shingles, received the Prix Galien USA 2013
Award for Best Biotechnology Product.

“Merck is honored to have been chosen as a recipient of this prestigious
award,” said Dr. Roger M. Perlmutter, president, Merck Research
Laboratories. “This achievement is a testament to the remarkable
contributions of everyone at Merck who played a role in helping to bring
ZOSTAVAX to market.”

The Prix
Galien Award
recognizes the pharmaceutical industry’s outstanding
achievement in the development of new medicines. An internationally
recognized award, the Prix Galien was founded in France in 1969 by
French pharmacist Roland Mehl and is considered the highest accolade for
pharmaceutical research and development.

This latest award for ZOSTAVAX is Merck’s sixth Prix Galien USA award in
seven years. The company was previously recognized for VICTRELIS
(2012)
, ROTATEQ (2010), ISENTRESS (2008), and JANUVIA and GARDASIL
(2007). In total, around the world, Merck has won the Prix Galien more
than 30 times, making Merck one of the two most-awarded companies of all
time.

About Merck

Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com
and connect with us on Twitter,
Facebook
and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Merck’s ability to accurately
predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other protections
for innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2012 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

Media:
Merck
Caroline Lappetito, (267) 305-7639

Unsubscribe from email alerts